PaxVax inks Swiss marketing accord with Seqirus for flu vaccines

Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a marketing and distribution agreement with Seqirus, which is part of Australian biotech firm CSL Limited (ASX: CSL).

Under the terms of this accord, PaxVax will market, sell and distribute two of Seqirus’ influenza vaccine products in Switzerland, namely Agrippal (surface antigen, inactivated) and Fluad (influenza vaccine, adjuvanted).

“PaxVax has deep expertise in the vaccine industry and has built a substantial global marketing, sales and distribution network that enables us to support vaccine makers serving major markets in North America and Europe,” said Nima Farzan, president and chief executive of PaxVax, adding: “We are pleased to partner with Seqirus, which is the second largest influenza vaccine manufacturer in the world, to ensure the availability of these important vaccines. With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market that includes our own typhoid vaccine, Vivotif.”